Get an overview of Pliant Therapeutics’ BEACON-IPF global clinical trial which aims to find out whether bexotegrast slows down or halts idiopathic pulmonary fibrosis disease progression over a 52-week treatment period by reducing scar formation (fibrosis) of the lungs.
Learn about previous clinical trial results, how to participate if you have idiopathic pulmonary fibrosis, and what to expect.
Find more pulmonary fibrosis clinical trial resources
**Gregory P. Cosgrove, M.D., FCCP, Pliant Therapeutics, Vice President, Clinical Development**
Dr. Cosgrove has over 20 years of pulmonary and critical care expertise in academic clinical research. Currently, he leads the Idiopathic Pulmonary Fibrosis (IPF) clinical development program at Pliant Therapeutics. Prior to joining Pliant, Dr. Cosgrove most recently served as the Chief Medical Officer of the Pulmonary Fibrosis Foundation, a leading advocacy group dedicated to patients and caregivers living with pulmonary fibrosis.